Cipla, the Mumbai-based pharmaceutical giant, reported a significant 55% year-on-year decline in consolidated net profit for the fourth quarter ending in March, amounting to ₹555 crore. The company's total income from operations also saw a 3% decrease, totaling ₹6,541 crore. For the full financial year 2026, Cipla experienced a 2% increase in revenue, reaching ₹28,163 crore, although profit after tax fell by 26% to ₹3,879 crore. Despite these challenges, Achin Gupta, the Managing Director and Global CEO, expressed confidence in the company's progress across various markets, highlighting strong growth in key therapies and maintaining leadership in consumer health brands. The board has proposed a final dividend of ₹13 per equity share for shareholders.